Published in Expert Rev Vaccines on October 01, 2011
Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine (2013) 1.56
Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine (2011) 0.98
A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One (2013) 0.96
Respiratory syncytial virus: current progress in vaccine development. Viruses (2013) 0.95
The Pneumonia Virus of Mice (PVM) model of acute respiratory infection. Viruses (2012) 0.93
Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther (2013) 0.91
Seasonality of acute otitis media and the role of respiratory viral activity in children. Pediatr Infect Dis J (2013) 0.91
A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5). Vaccine (2014) 0.86
A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS One (2015) 0.85
Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Hum Vaccin Immunother (2013) 0.83
A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment. Virol J (2013) 0.83
Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses. Expert Rev Vaccines (2015) 0.80
Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine (2014) 0.80
A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One (2015) 0.80
Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model. Hum Vaccin Immunother (2013) 0.78
Neonatal calf infection with respiratory syncytial virus: drawing parallels to the disease in human infants. Viruses (2012) 0.77
A Review of the CD4+ T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population. EC Microbiol (2015) 0.77
Mucosal vaccines against respiratory syncytial virus. Curr Opin Virol (2014) 0.77
Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination. Hum Vaccin Immunother (2015) 0.76
Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine. Mol Pharm (2015) 0.76
Antibody response to respiratory syncytial virus infection in children <18 months old. Hum Vaccin Immunother (2016) 0.76
Respiratory syncytial virus outbreak in the basic military training cAMP of the republic of Korea Air Force. J Prev Med Public Health (2015) 0.75
Influence of meteorological conditions on RSV infection in Portugal. Int J Biometeorol (2016) 0.75
Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children. Paediatr Drugs (2017) 0.75
In Vitro Evaluation of Glycoengineered RSV-F in the Human Artificial Lymph Node Reactor. Bioengineering (Basel) (2017) 0.75
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Regulatory T cells and immune tolerance. Cell (2008) 18.77
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet (2010) 13.86
T cell tolerance by clonal elimination in the thymus. Cell (1987) 13.83
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 10.85
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med (2005) 9.47
The burden of respiratory syncytial virus infection in young children. N Engl J Med (2009) 8.95
Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA (1999) 8.07
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 7.78
Respiratory syncytial virus and parainfluenza virus. N Engl J Med (2001) 7.69
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) (1991) 7.08
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol (1969) 6.85
CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol (2004) 6.80
Natural regulatory T cells in infectious disease. Nat Immunol (2005) 6.49
Humoral immunity due to long-lived plasma cells. Immunity (1998) 6.35
Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis (2007) 5.91
Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol (2000) 5.74
Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol (2003) 5.51
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature (1981) 5.00
Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol (1969) 4.97
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 4.93
Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med (2008) 4.70
Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. Nature (1988) 4.63
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature (2006) 4.59
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol (2007) 4.54
Genetic control of the antibody response: relationship between immune response and histocompatibility (H-2) type. Science (1969) 4.53
The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. Nature (1988) 4.43
Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr (2000) 4.08
Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr (1981) 4.00
Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev (2004) 3.98
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis (1991) 3.27
Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2007) 3.19
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol (1985) 2.87
Mitogen- and IL-4-regulated expression of germ-line Ig gamma 2b transcripts: evidence for directed heavy chain class switching. Cell (1988) 2.77
Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol (2000) 2.75
Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol (2001) 2.70
Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A (2010) 2.68
Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis (2000) 2.68
Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev (2010) 2.61
Immunity and immunological memory following smallpox vaccination. Immunol Rev (2006) 2.57
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 2.43
Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med (1997) 2.40
Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr (2007) 2.38
Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A (2010) 2.36
A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med (2002) 2.34
Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol (2002) 2.31
Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med (2008) 2.30
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis (1998) 2.24
Th1 and Th2 subsets: paradigms lost? Immunol Today (1995) 2.21
CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol (2001) 2.21
Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc (1992) 2.17
Defective antigen processing in GILT-free mice. Science (2001) 2.16
Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol (2005) 2.09
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr (1980) 2.07
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis (2008) 2.05
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev (2011) 2.04
The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol (2000) 2.04
US military smallpox vaccination program experience. JAMA (2003) 2.03
Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis (2004) 2.03
The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol (2010) 1.97
Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol (2004) 1.97
Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol (2001) 1.95
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol (2006) 1.94
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A (2010) 1.92
Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol (2010) 1.89
Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol (2006) 1.89
CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J Immunol (2005) 1.89
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine (2003) 1.83
Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine (1999) 1.83
Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol (1987) 1.83
Developing and maintaining protective CD8+ memory T cells. Immunol Rev (2006) 1.82
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J (2009) 1.80
Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis (2001) 1.78
Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep (2003) 1.76
Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol (2006) 1.73
Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity (2001) 1.69
FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature (2008) 1.62
Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol (2007) 1.61
Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol (1988) 1.60
CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol (2007) 1.57
The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine (2006) 1.57
Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS (2009) 1.56
Respiratory virus infection of mice provokes a permanent humoral immune response. J Virol (1994) 1.55
Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood (2007) 1.52
The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol (1994) 1.52